Neurodegeneration, Alzheimer's disease biomarkers, and longitudinal verbal learning and memory performance in late middle age
- PMID: 33765428
- PMCID: PMC8286465
- DOI: 10.1016/j.neurobiolaging.2021.01.030
Neurodegeneration, Alzheimer's disease biomarkers, and longitudinal verbal learning and memory performance in late middle age
Abstract
This study examined the effect of neurodegeneration, and its interaction with Alzheimer's disease (AD) cerebrospinal fluid biomarkers, on longitudinal verbal learning and memory performance in cognitively unimpaired (CU) late middle-aged adults. Three hundred and forty-two CU adults (cognitive baseline mean age = 58.4), with cerebrospinal fluid and structural MRI, completed 2-10 (median = 5) cognitive assessments. Learning and memory were assessed using the Rey Auditory Verbal Learning Test (RAVLT). We used sequential comparison of nested linear mixed effects models to analyze the data. Model selection preserved a significant ptau181/Aβ42 × global atrophy × age interaction; individuals with less global atrophy and lower ptau181/Aβ42 levels had less learning and delayed recall decline than individuals with more global atrophy and/or higher levels of ptau181/Aβ42. The hippocampal volume × age × ptau181/Aβ42 interaction was not significant. Findings suggest that in a sample of CU late middle-aged adults, individuals with AD biomarkers, global atrophy, or both evidence greater verbal learning and memory decline than individuals without either risk factor.
Keywords: Cerebrospinal fluid biomarkers; Global atrophy; Hippocampus; Preclinical Alzheimer's disease; Verbal learning; Verbal memory.
Published by Elsevier Inc.
Figures
References
-
- Akaike H. (1987). Factor analysis and AIC. In Selected Papers of Hirotugu Akaike (pp. 371–386). Springer.
-
- Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, … Petersen RC (2011). The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7(3), 270–279. - PMC - PubMed
-
- Allison SL, Koscik RL, Cary P, Jonaitis EM, Chin N, Rowley HA, Zetterberg H, Blennow K, Carlsson CM, Asthana S, Bendlin BB, & Johnson SC (2019). Comparison of different MRI-based morphometric estimates for defining neurodegeneration across the Alzheimer’s disease spectrum. NeuroImage: Clinical, 23, 101895. - PMC - PubMed
-
- Bäckman L, Jones S, Berger A-K, Laukka EJ, & Small BJ (2005). Cognitive impairment in preclinical Alzheimer’s disease: A meta-analysis. Neuropsychology, 19(4), 520. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
